[Question] Denmark — has anyone got a straight answer on 503B
Genuine question, and the title is the question: Denmark — has anyone got a straight answer on 503B. The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes. Compounded preparations are not approved products and carry…
Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.
Not convinced. You are comparing a compounded concentration with a branded one and assuming they match.
shortage status changes and the whole arrangement changes with it
potency testing on the finished preparation is the thing to ask for
the price difference is mostly the intake, not the vial